Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.

ABSTRACT:

Objective

We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2 years of exposure.

Research design and methods

Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR. Forty-six patients entered the 2-year extension study in which they continued their allocated therapy. Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period. Insulin sensitivity (M value) and β-cell function were measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic clamp with arginine stimulation at pretr

SUBMITTER: Bunck MC 

PROVIDER: S-EPMC3161303 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature